A globally recognized leader in pharmacovigilance and risk management, Shelley brings more than three decades of experience to her role at ELIQUENT Life Sciences. Shelley’s firsthand knowledge of regulatory expectations and her proficiency in navigating complex safety assessments and reporting challenges are invaluable to life science innovators.

Shelley’s extensive professional background includes more than 19 years of service at the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). During her tenure, Shelley served in multiple senior positions where she gained extensive knowledge of all European regulatory processes relating to monitoring the safety of licensed medicinal products and ancillary devices.

Shelley’s distinguished MHRA career included a role as the UK representative on the European Medicines Agency’s (EMA) EudraVigilance Expert Working Group. In this capacity, Shelley was instrumental in shaping key pharmacovigilance processes and systems across Europe. Her contributions helped enhance the capabilities of EudraVigilance, the EMA’s system for managing and analyzing information on suspected adverse reactions to medicines which are authorized or being studied in clinical trials in the European Economic Area (EEA).

Prior to joining ELIQUENT, Shelley served for more than 12 years as a strategic pharmacovigilance advisor to clients building and managing pharmacovigilance systems. In this role, Shelley provided pharmacovigilance and risk management support to biotechnology clients across a broad range of therapeutic areas. Her experience includes strategic and technical support in multiple markets from early clinical development to launch readiness. Clients benefited from Shelley’s deep knowledge of global requirements and expert insight on risk management strategies.

In her role at ELIQUENT, Shelley works with clients to ensure compliance with global safety standards, while anticipating changes, and preparing proactive solutions. Her deep understanding of drug safety and risk management protocols directly influences the long-term success of life science innovators.